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ABSTRACT
Objectives: The aim of the study was to assess the effect of 1 g ampicillin prophylactic dosage whether it is as effective as 
the dosage of 2 g to prevent maternal and neonatal morbidity in a randomized manner.
Materials and methods: One hundred and fourty eight singleton pregnant women with preterm premature rupture of 
membranes between 21 and 33 weeks of gestation were followed-up during the study period in our institution. We com-
pared the efficacy of two different different dosages of ampicillin. The study population was randomized into 2 groups. In 
the group 1, 1 g of intravenous ampicillin was given every 6 hours. In the group 2, 2 g of intravenous ampicillin was given 
every 6 hours. 
Results: There was no significant difference between groups interms of fetal complications (RDS, icterus, mortality, sepsis, 
transient tachypnea of newborn and the pneumonia), rate of intensive care unit admission, fetal gender, fever, rate of clinical 
chorioamnionitis, high white blood cell count and the CRP, rate of cases < 30 weeks (p > 0.05). There was a significant differ-
ence between the groups for the rate of previous preterm premature rupture of membranes history, steroid administration 
and the need for tocolysis (p < 0.05). 
Conclusions: Although antibiotics seems to be innocent, several side effects have been introduced. It is reasonable to use 
the lowest dosages in shortest period in order to minimize these unwanted effects.
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INTRODUCTION
Prelabor or premature rupture of membranes (PPROM) 
is defined as rupture of membranes before onset of labor [1]. 
One third of preterm deliveries are observed as a complication 
of PPROM. PPROM is associated with several complications 
for both neonate and the mother [1]. Most of these compli-
cations are seen in cases with PPROM before 34 weeks of 
gestation [2]. Latency period for the cases with PPROM under 
expectant management was reported to be 1.5–4.6 days 
[3–5]. Therefore majority of the cases deliver within 48 hours 
and some in 7 days following rupture of membranes [3–7]. 
Randomized trials have shown that neonatal complications 
can be reduced with prolongation of latency period [8, 9]. Evi-
dence based data lead the American College of Obstetricians 
and Gynecologists (ACOG) to prepare a clinical management 
guideline which recommends using prophylactic antibiotics 
to prolong pregnancy, reduce maternal infectious morbid-
ity and reduce infectious and gestational age dependent 
neonatal morbidity [1, 10]. Several antibiotic regimens have 
been proposed for PPROM prophylaxis including Ampicillin 
2 g intravenously every 6 hours for 48 hours or 7 days alone 
(ampicillin 2 g intravenously every 6 hours for 48 hours or 
7 days alone [11]. Dosages and the duration of prophylaxis 
for these kind of pregnancy complcation is still a debade.
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In this study, we tried to assess the effect of 1 g ampicillin 
prophylactic dosage whether it is as effective as the dosage 
of 2 g to prevent maternal and neonatal morbidity.
MATERIAL AND METHODS
This prospective randomized comperative study was 
conducted in the Department of Obstetrics and Gynecology 
at the Suleymaniye Women Health Research and Training 
Hospital, Istanbul, Turkey from January 1, 2011 to May 1, 
2013. The hospital is a tertiary referral center with about 
5600 deliveries per year. One hundred and fourty eight 
singleton pregnant women with PPROM between 21 and 
33 weeks of gestation were followed-up during the study 
period in our institution. We compared the efficacy of am-
picillin by the different dosages. The study population was 
randomized into 2 groups. In the group 1 (n = 84), 1 g of 
intravenous ampicillin was given every 6 hours. In the group 
2 (n = 74), 2 g of intravenous ampicillin was given every 
6 hours. Sample size was calculated according to the study 
by Charan J et al. with 95% CI and 80% power [12].
Diagnosis of PPROM was based on a history of leak-
ing fluid and visualization of amniotic fluid in the vagina. 
If PPROM was not obvious after inspection, the diagnosis 
was confirmed by positive results from a nitrazine test and 
ultrasonographic evaluation that demonstrated olighy-
dramnios. Exclusion criteria were cervial dilatation more 
than 4 cm, PPROM for > 48 hours before admission, major 
fetal anomaly, chorioamnionitis, severe preeclampsia, al-
lergic reaction to penicillin or any condition that would 
require the pregnancy to be terminated including maternal 
co-morbidity. In total, 158 patients were considered eligible 
for the study (Fig. 1). We compared the efficacy of two dif-
ferent dosages of ampicillin. The study included 2 groups. In 
the group 1, 1 g of intravenous ampicillin was given every 
6 hours. In the group 2, 2 g of intravenous ampicillin was 
given every 6 hours. All antibiotics were administered until 
delivery or up to 7 days. The patients with 24 weeks of ges-
tation or more were treated with antenatal corticosteroid 
due to prematurity. During the follow-up, vaginal culture 
was performed at admission. The heart rate was monitored 
twice a day. Ultrasound examination was performed and 
fetal presentation, fetal weight and amniotic fluid volume 
was examined daily. Biophysical scoring and Doppler ve-
locimetry were also performed when needed. Labor induc-
tion was prohibited prior to 34 weeks. Randomization was 
performed by using computer program (Randomization.
com). The Ethical Committee of the Bakirkoy Dr. Sadi Konuk 
Hospital reviewed and approved the trial protocol and all 
participants provided written informed consent. 
Data on the characteristics of the patients including 
maternal age, parity were collected. Gestational age at ad-
mission, gestational age at delivery, latency period were 
recorded. Additionally, we measured amniotic fluid index, 
white blood cell (wbc) count, C-reactive protein (CRP) level, 
rates of clinical chorioamnionitis, neonatal sepsis, neona-
tal pneumonia and respiratory distress syndrome (RDS). 
Clinical chorioamnionitis was diagnosed based on maternal 
temperature ≥ 38°C and two or more of the following condi-
tions: (1) uterine tenderness; (2) wbc count > 15 000/mm³; 
(3) foul-smelling vaginal discharge; (4) maternal tachycardia 
Assessed for eligibility (n = 165)
Randomized (n = 165)
Group 1
(1 gr of intravenous Ampicillin, every 6 hours)
(n = 88)
Group 2
(2 gr of intravenous Ampicillin, every 6 hours)
(n = 77)
4 patients were lost from follow-up
n = 84






Figure 1. Flow of patients through the trial
703
Ilker Kahramanoglu et al., A RCT for the dosage of ampicillin in PPROM
www. journals.viamedica.pl/ginekologia_polska
Table 1. Summary of some demographic and clinical characteristics of whole study population
Descriptive Statistics
N Minimum Maximum Mean Std. deviation
Age (years) 158 15 44 27.76 6.078
Gravidity 158 1 12 2.43 1.899
Parity 158 0 11 0.96 1.486
Gestational age at diagnosis (week) 158 19.00 36.43 31.2793 4.03371
Gestational age at delivery (week) 158 20.29 39.00 32.0371 3.81235
Interval 158 0 53 5.30 8.265
Latency period (day) 158 0 40 5.45 7.118
Initial AFI 158 0 200 60.31 34.358
Apgar score at 1 minute 158 0 9 6.20 1.780
Apgar score at 1 minute < 4 158 1 2 1.93 0.253
Apgar score at 5 minutes 158 0 10 7.78 1.744
Apgar score at 5 minutes < 7 158 1 2 1.89 0.309
Duration of hospitalization of mother (day) 158 1 42 7.55 7.152
Birth weight [g] 158 280 3380 1910.62 647.898
(< 100 beats/min); and (5) fetal tachycardia (> 160 beats/min) 
as previously described (III). RDS was diagnosed in symp-
tomatic infants who required ventilator support for at least 
24 hours. Neonatal sepsis was diagnosed if there was a posi-
tive blood culture result obtained during the first 72 hours 
after birth. Pneumonia was diagnosed when an infant had 
compatible symptoms with diagnostic X-ray findings.
Statistical analysis was done using statistical software 
(SPSS 10.0 for Windows) and Student’s t-test, Mann-Whit-
ney U test, McNemar’s test and Friedman variance analysis 
were used, as appropriate. Signifance level was defined as 
0.05. Data were expressed as mean ± SD and percent (%), 
where appropriate. 
RESULTS
Some demographic and the clinical data for the whole 
study population is summarized in Table 1. 
There was no significant difference between groups in 
terms of fetal complications (RDS, icterus, mortality, sepsis, 
transient tachypnea of newborn and the pneumonia), rate 
of intensive care unit admission, fetal gender, fever, high 
white blood cell count (23/84 vs. 24/74) and the CRP, rate of 
cases < 30 weeks (23/84 vs. 22/74), the rate of previous PPROM 
history, steroid administration (39 vs. 55, respectively) and the 
need for tocolysis (10 vs. 2, respectively) (p > 0.05, Tab. 2). There 
was a significant difference between the low and high dosages 
groups for clinical choriamnionitis (18/84 vs. 8/74, p < 0.05).
DISCUSSION
In this study, we tried to compare two different dos-
ages of same agent in cases with preterm premature rup-
ture of membranes, our study revealed that two regimens 
result in similar outcomes except for the APGAR score at 
1st minute, PPROM history, need for tocolyses and ster-
oids. PPROM is seen in %2.0–3.5 of pregnancies and 1/3 of 
them result in preterm labor [13]. Prematurity is the most 
important cause of poor pregnancy outcome. Preterm de-
liveries account for 7 to 11% of the pregnancies [14, 15]. 
For that reason, management of PPROM is important for 
both prevention of preterm deliveries and the perinatal 
infections. Antibiotherapy provides interval for steroid ad-
ministration. According to the literature, it is well known 
that steroid administration has some benefits of lower rates 
of respiratory distress syndrom, intraventricular hemorrha-
gia, necrotizing enterocolitis, need for neonatal respiratory 
support. Steroid administration is effective in up to 30 to 
60% of the cases to prevent afforementioned complica-
tions [16, 17]. In a systematic review comparing antibiotics 
to placebo in the management of PPROM, analyses of the 
data revealed significantly lower chorioamnionitis rates (RR 
0.66, 95% CI 0.46–0.96), neonatal infections (RR 0.67, 95% 
CI 0.52–0.85), need for surfactant administration (RR 0.83, 
95% CI 0.72–0.96), need for neonatal respiratory support 
(RR 0.88, 95% CI 0.81–0.96) and probability of abnormal 
findings in cerebral ultrasound performed just before dis-
charge (RR 0.81, 95% CI 0.68–0.98), in group under antibiotic 
prophylaxis [18]. Antibiotics seem to be beneficial in the 
management of PPROM [9, 18]. On the other hand, Cochrane 
review showed that antibiotics could decrease short term 
neonatal morbidities but not perinatal mortality [19]. There 
is still a concern about the optimal effective antibiotic agent 
and the dosage, there is still need for further studies on 
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this issue [20]. There have been studies on the antiobiotics 
including ampicillin, amoxicillin, azithromycin and erithro-
mycin [9, 20, 21]. Comparison of ampicilin + erithromycin 
and ampicilin+azithromycin combinations revealed similar 
results. [21]. In an other study, eryhromycin was found to be 
associated with the higher risk for functional disorders and 
the cerebral palsy [8]. Amoxicillin-clavulanic acid combina-
tion resulted in higher rates of necrotizing enterocolitis in 
some studies [8, 22]. Due to the effectiveness on group 
B streptococcus, aerobic gram negative bacils and some 
anaerobic species, ampicillin is the most frequently used 
agent in PPROM prophylaxis [23]. According to the results of 
National Institute of Child Health and Human Development 
(NICHD) Maternal-Fetal Medicine Units (MFMU) Network trial 
on antibiotic therapy for reduction of infant morbidity after 
PPROM, ampicillin is recommended in 2 g doses for each 
6 hours intervals [9]. In our study we compared two differ-
ent dosages of ampicillin and found no difference in terms 
of maternal infections or neonatal poor outcome. The rate 
of chorioamnionitis was found to be higher in group under 
low dose protocol, however this difference did not reach 
statistical significance. It is well known that long duration 
and high doses of antibiotics may result in unfavorable out-
come including allergic reactions, gastrointestinal disorders, 
cardiac arythmias and even mortality [24]. Major problem 
in using high doses of antibiotics for long time is higher 
risk for development of multiresistant bacterias [25, 26]. For 
example in England, frequently used agent erythromycin 
resulted in development of 35% resistant bacterias [27, 
28]. In addition, overuse of antibiotics may be associated 
with the anaphylactic reactions during pregnancy and the 
peripartum period (2,7 cases/100.000 deliveries) [29–31]. 
Table 2. Comparison summary of some demographic and clinical characteristics of two groups
Group Statistics




Low Dose 84 27.5 5.8 0.6
High Dose 74 28.1 6.3 0.7 NS
Gravidity
Low Dose 84 2.5 1.9 0.2
High Dose 74 2.4 1.8 0.2 NS
Parity
Low Dose 84 0.9 1.3 0.1
High Dose 74 1 1.5 0.2 NS
Gestational age at diagnosis (week)
Low Dose 84 31 4.4 0.5
High Dose 74 31.6 3.5 0.4 NS
Gestational age at delivery (week)
Low Dose 84 31.8 4.2 0.5
High Dose 74 32.3 3.4 0.4 NS
Interval
Low Dose 84 5.5 8.5 0.9
High Dose 74 5 7.9 0.9 NS
Latency period (day)
Low Dose 84 5.6 8.1 0.8
High Dose 74 5.2 5.9 0.6 NS
Initial AFI [mm]
Low Dose 84 63.06 34.1 3.7
High Dose 74 57.22 34.6 4 NS
Apgar score at 1 minute
Low Dose 84 6.51 2 0.2
High Dose 74 5.79 1.2 0.1 < 0.05
Apgar score at 1 minute < 4
Low Dose 84 1.91 0.2 0.03
High Dose 74 1.96 0.1 0.02 NS
Apgar score at 5 minute
Low Dose 84 7.9 2.1 0.3
High Dose 74 7.5 0.8 0.1 NS
Apgar score at 5 minute <7
Low Dose 84 1.9 0.2 0.034
High Dose 74 1.8 0.3 0.044 NS
Duration of hospitalization of mother (day)
Low Dose 84 7.4 7.3 0.8
High Dose 74 7.6 6.9 0.8 NS
Birth weight [g]
Low Dose 84 1958.1 685.2 81.3
High Dose 74 1856.1 603.2 76.6 NS
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Anaphylaxis is a condition that threatenes both maternal 
and the fetal oxygenization. According to some studies, 
during the fetal and neonatal period, long term and high 
dose antibiotic exposure may result in allergic disease and 
abnormal intestinal flora development that may interfere 
with the immune system development [32–34]. Again ac-
cording to the Cochrane review, beta lactam antibiotics 
with or without combination of macrolide were found to 
be associated with the higher rates of neonatal death com-
pared to combinations without beta lactams (RR: 1.51; 95% 
CI = 1.06–2.15; NNTH: 143; 95% CI = 63–1250) [19].
In conclusion, antibiotic use seems to decrease neo-
natal morbidity in the management of PPROM. Although 
antibiotics seems to be innocent, several side effects have 
been reported. It is reasonable to use the lowest dosages in 
shortest period in order to minimize these unwanted effects 
while the half dosage (1 g of intravenous ampicillin, every 
6 hours) is as effective as the present recommendation (2 g 
ampicillin, every 6 hours).
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